Company Overview

SIGA Technologies, Inc. is a U.S.-based biotechnology company focused on the development, commercialization, and manufacture of antiviral medicines for the treatment of serious infectious diseases, particularly those associated with public health emergencies. The company operates within the biopharmaceutical and public health preparedness sectors, with a primary emphasis on countermeasures against orthopoxviruses. SIGA’s core product is TPOXX® (tecovirimat), an antiviral approved for the treatment of smallpox and authorized or approved in multiple jurisdictions for related orthopoxvirus infections, including mpox. The company’s revenue is predominantly driven by government procurement contracts and stockpiling programs rather than traditional commercial pharmaceutical sales.

SIGA was founded in 1995 and initially pursued a broader antiviral research strategy before narrowing its focus to biodefense and emerging infectious diseases following increased U.S. government investment in medical countermeasures. Over time, the company aligned its business model closely with U.S. and international public-sector customers, positioning itself as a specialized supplier of antiviral preparedness solutions. Its strategic advantage lies in its regulatory approvals, long-standing government relationships, and established manufacturing and supply infrastructure for a critical, limited-competition product.

Business Operations

SIGA operates primarily through a single-reportable operating segment focused on antiviral therapeutics for orthopoxviruses, centered on the development and commercialization of TPOXX® in oral and intravenous formulations. Revenue generation is largely contract-based, derived from procurement agreements with U.S. government agencies for national stockpiles, as well as sales to international governments and global health organizations. The company does not maintain a traditional commercial sales force, reflecting its concentration on institutional and governmental customers.

Operations are conducted through a lean internal structure, with research and development, regulatory strategy, and supply chain oversight managed internally, while manufacturing is largely outsourced to qualified third-party contract manufacturers. SIGA maintains long-term relationships with U.S. government agencies, including those involved in public health emergency preparedness, and collaborates with international regulatory bodies to support product approvals and procurement outside the United States. Public disclosures do not indicate the existence of material operating subsidiaries; the company conducts its business primarily through the parent entity.

Strategic Position & Investments

SIGA’s strategic direction is centered on maximizing the lifecycle value of TPOXX® through label expansions, additional regulatory approvals, and broader geographic adoption. Key initiatives include supporting approvals for multiple orthopoxvirus indications, maintaining readiness for rapid deployment during outbreaks, and securing multi-year procurement contracts with governmental customers. The company has invested in both oral and intravenous formulations to address diverse patient populations and clinical settings.

Rather than pursuing large-scale acquisitions, SIGA has focused on internal investment in regulatory, clinical, and manufacturing capabilities related to its core antiviral platform. Its strategic positioning benefits from high barriers to entry, including regulatory exclusivity, specialized know-how, and entrenched customer relationships. Public sources do not indicate a diversified portfolio of subsidiary or equity investments; the company’s value proposition remains tightly linked to its flagship product and its role in global biodefense and outbreak response infrastructure.

Geographic Footprint

SIGA Technologies is headquartered in New York City, United States, and its operational influence extends internationally through government and institutional customers. While the majority of revenue historically originates from the United States, particularly federal agencies responsible for health security and defense, the company also supplies Europe, Canada, Asia-Pacific, and other regions through direct government contracts and international health organizations.

The company does not operate large physical facilities abroad, instead leveraging international regulatory approvals and global manufacturing and distribution partners to serve non-U.S. markets. Its geographic footprint is therefore characterized more by market reach and contractual presence than by owned infrastructure, reflecting its focus on centralized oversight and global deployment capability.

Leadership & Governance

SIGA is led by an executive team with experience in biotechnology, government contracting, and antiviral research, reflecting the company’s specialized focus. Leadership emphasizes regulatory credibility, operational discipline, and long-term alignment with public-sector health priorities. The board and management team oversee strategy with a focus on preparedness, compliance, and financial sustainability rather than rapid product diversification.

Key executives include:

• Eric L. Messman – Chief Executive Officer
• Dennis E. Hruby, Ph.D. – Chief Scientific Officer
• Phillip B. Gomez – Chief Financial Officer

Founder information and certain historical executive roles are referenced inconsistently across public disclosures; data inconclusive based on available public sources.